Skip to main content

PD-L1 IHC 28-8 pharmDx「ダコ」の概要

More Personalized Cancer Results. One Test Makes it Possible.
Agilent Dako
Key benefits of PD-L1 IHC 28-8 pharmDx
  • Broad Utility: Evidence based PD-L1 testing across multiple cancer types
  • Clinically relevant PD-L1 results linked to clinical outcomes
  • Unrivaled quality and reliability
  • Standardized and fully validated kit
Product Information

Product details, specification sheet and safety data sheet (SDS).

Experience the easy integration of PD-L1 in your IHC workflow
  • Integrate PD-L1 IHC 28-8 pharmDx without changing staining lab workflow
  • Ready-to-use reagents and cell line controls optimized for Autostainer Link 48
  • Pre-programmed, validated protocol

Gastric cancer

Click here to download Manual and Brochure

Non-small cell lung cancer (NSCLC)

Click here to download Manual and Brochure

Non squamous non-small cell lung cancer (nsNSCLC)

Click here to download Manual and Brochure

Head-and-neck cancer (HNC)

Click here to download Manual and Brochure


Click here to download Manual and Brochure

pd l1 ihc workflow teaser image Want to hear more about PD-L1 IHC 28-8 pharmDx?

Contact your local sales representative.

Kit Components

PD-L1 IHC 28-8 pharmDx is a complete kit with reagents sufficient for 50 tests (50 slides incubated with primary antibody to PD-L1 and 50 slides incubated with the corresponding Negative Control Reagent) and 15 Control Slides for use on Autostainer Link 48.

Kit Components teaser image
  • EnVision FLEX Target Retrieval Solution, Low pH, 50x
  • Peroxidase-Blocking Reagent
  • Monoclonal Rabbit Anti-PD-L1, Clone 28-8
  • Negative Control Reagent
  • PD-L1 IHC 28-8 pharmDx Rabbit LINKER
  • Visualization Reagent-HRP
  • DAB+ Substrate Buffer
  • DAB+ Chromogen
  • DAB Enhancer
  • Control Slides
Order Information



PD-L1 IHC 28-8 pharmDx


Required but not included in the kit:

Autostainer Link 48

EnVision FLEX Wash Buffer, 20x

EnVision FLEX Hematoxylin (Link)

PT Link

PT Link Rinse Station






Intended Use

For in vitro diagnostic use.

To measure the proportion of PD-L1 expression in cancer tissue or cells

  • Indication as an aid for proper administration of nivolumab [recombinant] in non-small cell lung cancer [NSCLC] patients, head-and-neck cancer patients, and gastric cancer patients
  • Indication as an aid for proper administration of nivolumab [recombinant] and ipilimumab combination in melanoma patients

It is desirable to measure PD-L1 expression by 28-8 kit in determining whether or not the following drugs can be administered.

  • Nivolumab [recombinant] for patients with non-squamous NSCLC or head-and-neck cancer who have been treated with chemotherapy previously
  • Combination therapy of nivolumab [recombinant] and chemotherapy for NSCLC patients or gastric cancer patients who have not been treated with chemotherapy
  • Combination therapy of nivolumab [recombinant] and ipilimumab for melanoma patients

If it is not possible to measure PD-L1 expression using PD-L1 IHC 28-8 pharmDx, refer to the packaging insert of the drugs, and appropriately judge the adequacy of administration.

See the OPDIVO® product label for specific clinical circumstances guiding PD-L1 testing